Summary
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Official Title
A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Keywords
Neoplasms, Ovarian, Platinum-resistant ovarian cancer (PROC), Primary peritoneal cancer, Fallopian tube cancer, MORAb-202, Folate-receptor alpha, ADC, Antibody-drug conjugate, Epithelial ovarian cancer, High grade serous, Farletuzumab ecteribulin, Fallopian Tube Neoplasms, Ovarian Neoplasms, Paclitaxel, Doxorubicin, Liposomal doxorubicin, Topotecan, Farletuzumab, Pegylated Liposomal Doxorubicin (PLD)